Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Bypassing inositol polyphosphate 4-phosphatase type II-mediated chemoresistance and leukemic stemness in Acute Myeloid Leukemia via cotreatment with lysosomal inhibitors.
FY 2021-22
Summary
Acute Myeloid Leukemia (AML) is a common, aggressive type of leukemia. The progression of AML depends on the function of cells called leukemic stem cells (LSCs). Research shows that AML patients with high LSC content have an aggressive form of AML and have lower survival rates than patients with low LSC content. As such, it is necessary to investigate therapies that target LSCs to improve AML patient outcomes. Recent studies in our research group identified that AML patients with very aggressive disease and poor health outcomes have high levels of a protein called INPP4B. INPP4B is also reported to play a role in lysosomal function and activity. Additionally, previous research shows that lysosomal function is important to LSCs function. However, there is limited research linking LSCs, INPP4B overexpression, and lysosomal function to AML prognosis. This study aims to identify the role of INPP4B overexpression in lysosomal function and LSC content in AML. It is hypothesized that INPP4B overexpression plays a critical function in LSCs and promotes AML progression by altering lysosomal function. This study examines signalling alterations, lysosomal functions, and AML progression using mouse models of leukemia. Additionally, lysosomal inhibitors will be introduced to measure their role in AML progression. This research is significant as it aims to identify molecular pathways impacted by INPP4B in the hopes of generating new AML therapies that block INPP4B function and eliminate LSCs.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466934
Name
Newell Candaice A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Bypassing inositol polyphosphate 4-phosphatase type II-mediated chemoresistance and leukemic stemness in Acute Myeloid Leukemia via cotreatment with lysosomal inhibitors.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia (Aml); Cancer; Cell Signalling; Chemoresistance; Inpp4b; Leukemia Stem Cells; Lysosome; Mouse Model; Phosphoinositide Signalling
Abstract
Acute Myeloid Leukemia (AML) is a common, aggressive type of leukemia. The progression of AML depends on the function of cells called leukemic stem cells (LSCs). Research shows that AML patients with high LSC content have an aggressive form of AML and have lower survival rates than patients with low LSC content. As such, it is necessary to investigate therapies that target LSCs to improve AML patient outcomes. Recent studies in our research group identified that AML patients with very aggressive disease and poor health outcomes have high levels of a protein called INPP4B. INPP4B is also reported to play a role in lysosomal function and activity. Additionally, previous research shows that lysosomal function is important to LSCs function. However, there is limited research linking LSCs, INPP4B overexpression, and lysosomal function to AML prognosis. This study aims to identify the role of INPP4B overexpression in lysosomal function and LSC content in AML. It is hypothesized that INPP4B overexpression plays a critical function in LSCs and promotes AML progression by altering lysosomal function. This study examines signalling alterations, lysosomal functions, and AML progression using mouse models of leukemia. Additionally, lysosomal inhibitors will be introduced to measure their role in AML progression. This research is significant as it aims to identify molecular pathways impacted by INPP4B in the hopes of generating new AML therapies that block INPP4B function and eliminate LSCs.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Newell, Candaice A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~